OK, well the janssen Component makes sense because the dual therapy that ViiV Has been a part of uses dolutegravir (ViiV) and rilpivirine ((Janseen/J&J).

Interestingly, Gilead had a combination drug of Their drugs tenofovir, viread and Janssen’s drug rilpivirine called “Complera” And it was co-marketed. The marketing angle in addition to efficacy was the side effect profile was favorable..

ViiV Recently has been working to box out viread (Gilead) with their dual therapy initiative that uses dolutegravir With another ART and they have used it with rilpivirine to some success.

The HIV cure initiative with LL and theBNabs Stated that multiple ARV regimens were used.. So maybe there Dual therapy regimens, and triple therapy regimens that included dolutegravir and rellpivarine as well as biktarvy. I am extremely interested to know how each of those regimens compared against one another.


I suspect the study was not powered with enough subjects to be able to tease out if dual therapy versus triple therapy had any implication, but I’d still like to see the data..

Regardless, this takes my thought thatLamividine, Which is an older and allegedly more toxic regimen out of the equation and replaces it with relpivarine /dtg (dolutegravir)